Trial Profile
A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 01 Nov 2020 Primary endpoint has not been met. (Area of punctate mechanical hyperalgesia in capsaicin-responders)
- 07 Oct 2015 Accrual to date is 66% according to United Kingdom Clinical Research Network.
- 04 Sep 2015 Accrual to date is 58% according to United Kingdom Clinical Research Network.